These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
98 related articles for article (PubMed ID: 20206721)
1. Anticoagulant activity of enzymatically synthesized amylose derivatives containing carboxy or sulfonate groups. Takahara J; Hosoya K; Sunako M; Hirohara S; Terada K; Ando T; Tanihara M Acta Biomater; 2010 Aug; 6(8):3138-45. PubMed ID: 20206721 [TBL] [Abstract][Full Text] [Related]
2. Experimental study on anticoagulant and antiplatelet aggregation activity of a chemically sulfated marine polysaccharide YCP. Han F; Yao W; Yang X; Liu X; Gao X Int J Biol Macromol; 2005 Sep; 36(4):201-7. PubMed ID: 16102810 [TBL] [Abstract][Full Text] [Related]
3. An algal sulfated galactan has an unusual dual effect on venous thrombosis due to activation of factor XII and inhibition of the coagulation proteases. Melo FR; Mourão PA Thromb Haemost; 2008 Mar; 99(3):531-8. PubMed ID: 18327401 [TBL] [Abstract][Full Text] [Related]
4. Aging and venous thromboembolism influence the pharmacodynamics of the anti-factor Xa and anti-thrombin activities of a low molecular weight heparin (nadroparin). Mismetti P; Laporte-Simitsidis S; Navarro C; Sié P; d'Azemar P; Necciari J; Duret JP; Gaud C; Decousus H; Boneu B Thromb Haemost; 1998 Jun; 79(6):1162-5. PubMed ID: 9657442 [TBL] [Abstract][Full Text] [Related]
5. Is the inhibition of both clot-associated thrombin and factor Xa more clinically relevant than either one alone? Meddahi S; Samama MM Blood Coagul Fibrinolysis; 2009 Apr; 20(3):207-14. PubMed ID: 19657318 [TBL] [Abstract][Full Text] [Related]
6. Anticoagulant and anti-platelet activity of polyphenolic-polysaccharide preparation isolated from the medicinal plant Erigeron canadensis L. Pawlaczyk I; Czerchawski L; Kuliczkowski W; Karolko B; Pilecki W; Witkiewicz W; Gancarz R Thromb Res; 2011 Apr; 127(4):328-40. PubMed ID: 21172723 [TBL] [Abstract][Full Text] [Related]
8. The activity of unfractionated heparin and low molecular weight heparins in rabbit plasma--the need for using absolute anti-factor Xa and antithrombin activities. Peyrou V; Béguin S; Boneu B; Hemker HC Thromb Haemost; 1997 Feb; 77(2):312-6. PubMed ID: 9157588 [TBL] [Abstract][Full Text] [Related]
9. Heparin chain-length dependence of factor Xa inhibition by antithrombin in plasma. Rezaie AR Thromb Res; 2007; 119(4):481-8. PubMed ID: 16515805 [TBL] [Abstract][Full Text] [Related]
11. Preparation and anticoagulation activity of sodium cellulose sulfate. Wang ZM; Li L; Zheng BS; Normakhamatov N; Guo SY Int J Biol Macromol; 2007 Oct; 41(4):376-82. PubMed ID: 17602735 [TBL] [Abstract][Full Text] [Related]
12. [The Choay domain -- the structure responsible for the anticoagulant action of heparins]. Hemker HC; al Dieri R; Wagenvoord R; Béguin S Bull Acad Natl Med; 2003; 187(1):59-66; discussion 66-7. PubMed ID: 14556454 [TBL] [Abstract][Full Text] [Related]
13. Anticoagulant mechanisms of covalent antithrombin-heparin investigated by thrombelastography. Comparison with unfractionated heparin and low-molecular-weight heparin. Atkinson HM; Mewhort-Buist TA; Berry LR; Chan AK Thromb Haemost; 2009 Jul; 102(1):62-8. PubMed ID: 19572069 [TBL] [Abstract][Full Text] [Related]
14. Serpin-independent anticoagulant activity of a fucosylated chondroitin sulfate. Glauser BF; Pereira MS; Monteiro RQ; Mourão PA Thromb Haemost; 2008 Sep; 100(3):420-8. PubMed ID: 18766257 [TBL] [Abstract][Full Text] [Related]
15. Effect of new synthetic heparin mimetics on whole blood thrombin generation in vivo and in vitro in rats. Hérault JP; Bernat A; Gaich C; Herbert M Thromb Haemost; 2002 Feb; 87(2):238-44. PubMed ID: 11858483 [TBL] [Abstract][Full Text] [Related]
16. Effects of sulfation on antithrombin-thrombin/factor Xa interactions in semisynthetic low molecular weight heparins. Sissi C; Naggi A; Torri G; Palumbo M Semin Thromb Hemost; 2001 Oct; 27(5):483-7. PubMed ID: 11668417 [TBL] [Abstract][Full Text] [Related]
17. Heparin and low molecular weight heparins inhibit prothrombinase formation but not its activity in plasma. Ofosu FA; Lormeau JC; Craven S; Dewar L; Anvari N Thromb Haemost; 1994 Dec; 72(6):862-8. PubMed ID: 7740455 [TBL] [Abstract][Full Text] [Related]
18. Synthetic heparin derivatives as new anticoagulant drugs. de Kort M; Buijsman RC; van Boeckel CA Drug Discov Today; 2005 Jun; 10(11):769-79. PubMed ID: 15922935 [TBL] [Abstract][Full Text] [Related]
19. Direct inhibitors of coagulation proteins - the end of the heparin and low-molecular-weight heparin era for anticoagulant therapy? Laux V; Perzborn E; Heitmeier S; von Degenfeld G; Dittrich-Wengenroth E; Buchmüller A; Gerdes C; Misselwitz F Thromb Haemost; 2009 Nov; 102(5):892-9. PubMed ID: 19888525 [TBL] [Abstract][Full Text] [Related]
20. Histones Differentially Modulate the Anticoagulant and Profibrinolytic Activities of Heparin, Heparin Derivatives, and Dabigatran. Ammollo CT; Semeraro N; Carratù MR; Colucci M; Semeraro F J Pharmacol Exp Ther; 2016 Feb; 356(2):305-13. PubMed ID: 26578266 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]